Show/Hide Menu

Management team

Open and complete information on a routine basis is a guiding principle for the cooperation of MorphoSys’s Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their stated objective is the sustainable increase in the company’s value.

Management Board

MorphoSys was co-founded in 1992 by today's CEO, Dr. Simon Moroney. Through the joint effort of the entire Management Board, the company has become one of the leading biopharmaceutical companies worldwide.

Dr. Simon E. Moroney

Chief Executive Officer

Biography

Dr. Simon E. Moroney

Chief Executive Officer

Dr. Moroney is one of the Company’s co-founders. Prior to that, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, UK, as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada, and as Associate in the Chemistry Department of the ETH in Zurich, Switzerland, where he also held a position as Lecturer. He was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.

Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D.Phil. in Chemistry.

In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Moroney currently does not hold any other board memberships.

Jens Holstein

Chief Financial Officer

Biography

Jens Holstein

Chief Financial Officer

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

He currently does not hold any other board memberships.

Dr. Arndt Schottelius

Chief Development Officer

Biography

Dr. Arndt Schottelius

Chief Development Officer

Dr. Schottelius joined MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of Immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development. Prior to his position at Genentech, Dr. Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany.

Dr. Schottelius received his PhD and MD degrees from the University of Freiburg, Germany. Subsequently, he practiced medicine as a resident physician in gastroenterology at the Charité-Universitätsmedizin Berlin, Germany, and held a research fellowship from the Crohn’s & Colitis Foundation of America at the University of North Carolina before moving into the pharmaceutical industry.

Dr. Schottelius currently does not hold any other board memberships.

Dr. Marlies Sproll

Chief Scientific Officer

Biography

Dr. Marlies Sproll

Chief Scientific Officer

Dr. Sproll joined MorphoSys as R&D department head in 2000. In 2005, she was promoted to Chief Scientific Officer. Her current areas of responsibility include technology development, discovery, manufacturing, alliance management and intellectual property.

Before joining MorphoSys AG, Dr. Sproll held various R&D positions in the pharmaceutical industry, e.g. at the Vienna research facility of Boehringer Ingelheim and at E. Merck KGaA in Darmstadt, Germany, focusing on the discovery and development of antibody-based drugs and cancer vaccines.

Dr. Sproll studied Biology and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. Before joining the industry, she held various research positions at different institutes of the Max-Planck Society in Tübingen, Germany.

Dr. Sproll acts as member of the Supervisory Board of LanthioPharma, Groningen, Nederlands.

Related links

Supervisory Board

The Supervisory Board oversees and advises the Management Board. The Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries.

Dr. Gerald Möller

Chairman

Biography and additional memberships

Dr. Gerald Möller

Chairman

Year of birth 1943
Nationality German
Place of residence Heidelberg, Germany

Professional Development

Currently Independent Management Consultant in the Life Sciences and Healthcare Industries, Heidelberg, Germany
Since 2002 Advisor HBM Partners, Zug, CH
1999 – 2000 CEO & Chairman, 4sigma Ltd, Bermuda
1995 – 1998 CEO, Boehringer Mannheim Group, Amsterdam, NL
1994 CEO, Boehringer Mannheim Therapeutics
1992 – 1993 President, Advanced Diagnostics & Biochemicals, Boehringer Mannheim GmbH, CTO Corange Ltd
1988 – 1992 President, Decentralized Diagnostics, Boehringer Mannheim GmbH
1986 – 1987 President, Biochemicals & R&D, Boehringer Mannheim Corp, Indianapolis, USA
1980 – 1985 Several functions in Diagnostic R&D, Boehringer Mannheim GmbH; 1985 Head of all Diagnostic R&D
1978 – 1979 Director, Scientific Department, Boehringer Mannheim Yamanaouchi K.K., Tokyo, Japan
1975 – 1977

Group Leader, Boehringer Mannheim GmbH

Education

1975 PhD, Institute for Physical Chemistry
1970 – 1975 Scientific assistant at the Institute for Physical Chemistry
1970 Diploma in Chemistry, Institute for Physical Chemistry
1965 – 1970 Student at University of Kiel, Chemistry

Membership in other Supervisory Boards and other current mandates

4sigma Inc.*, Bermuda Chairman of the Board of Directors
Adrenomed AG, Germany Member of the Supervisory Board
Genticel SA*, France Deputy Chairman of the Supervisory Board
Illumina, Inc.*, USA Member of the Board of Directors
Invendo Medical GmbH*, Germany Chairman of the Advisory Board

Dr. Möller is a member of MorphoSys AG's Supervisory Board since 1999.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Dr. Geoffrey Vernon

Deputy Chairman

Biography and additional memberships

Dr. Geoffrey Vernon

Deputy Chairman

Year of birth 1952
Nationality British
Place of residence Devon, UK

Professional Development

Since 1998 CEO and Chairman, Business Consultant at Ziggus Holdings Ltd., UK
1994 - 1998 Executive Director, Rothschild Asset Management Ltd., UK
1988 - 1994

Partner, Advent Venture Capital Ltd., UK

1984 - 1987 Business Development Manager, Ciba-Geigy Pharmaceuticals, UK
1982 - 1984 Commercial Development Manager, Schering Chemicals Ltd., UK
1980 - 1982 Product Manager, Travenol Laboratories Ltd., UK
1976 - 1980 Hospital Pharmacist, National Health Service

Education

1977 PhD
 

Dr. Vernon holds a B.Pharm, Ph.D., and a M.B.A degree. He is the first Director in Great Britain to be accredited as a Chartered Director. He is a Fellow of the Institute of Directors and of the Royal Pharmaceutical Society.

Membership in other Supervisory Boards and other current mandates

Veryan Medical Ltd.*, UK Non-Executive Chairman of the Board of Directors
Ziggus Holdings Ltd.*, UK Non-Executive Chairman of the Board of Directors

Dr. Vernon is a member of MorphoSys AG's Supervisory Board since 1999.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Dr. Walter Blättler

Member

Biography and additional memberships

Dr. Walter Blättler

Member

Year of birth 1949
Nationality Swiss and American
Place of residence Brookline, MA, USA

Professional Development

Currently Independent Management Consultant in the Life Sciences Industry, Brookline, MA, USA
2012 - 2014 Vice President, Development, CoStimm Pharmaceuticals Inc., Brookline, MA, USA
2011 - 2012 Independent Scientific Consultant
2009 - 2011 Director, Pre-clinical Development, Alfama, MA, USA
2007 - 2009 Consultant to HealthCare Ventures (HCV) and Edmond de Rothschild Investment Partners (EdRIP)
1996 - 2007 Executive Vice President, Science and Technology, ImmunoGen, Inc. Cambridge, MA, USA
1994 - 1996 Senior Vice President, Research and Development, ImmunoGen, Inc. Cambridge, MA, USA
1995 - 2006 Member of the Supervisory Board of ImmunoGen, Inc. Cambridge, MA, USA
1987 - 1994 Vice President Research, ImmunoGen, Inc. Cambridge, MA, USA
1987 - 1996 Lecturer in Pathology, Division of Tumor Immunology, Dana-Farber Cancer Institute, Harvard Medical School, USA
1986 - 1987 Assistant Professor in Pathology, Division of Tumor Immunology, Dana-Farber Cancer Institute, Harvard Medical School, USA
1981 - 1986 Assistant Professor in Pathology, Division of Tumor Immunology, Dana-Farber Cancer Institute, Harvard Medical School, USA

Education

1978 - 1981 Postdoctoral Fellow, Chemistry Department, Harvard University, Cambridge, MA, USA
1978 Dr.sc.nat. (Chemistry) Swiss Federal Institute of Technology, Zurich (ETH Zürich); Awarded the ETH Zürich Silver Medal for outstanding thesis
1973 M.S. (Chemistry) Swiss Federal Institute of Technology, Zurich (ETH Zürich)

Membership in other Supervisory Boards and other current mandates

AvidBiologics, Inc.*, Canada Board Member, Chief Advisor R&D

Dr. Blättler is a member of MorphoSys AG's Supervisory Board since 2007.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Dr. Daniel Camus

Member

Biography and additional memberships

Dr. Daniel Camus

Member

 Year of birth 1952
Nationality French and Canadian
Place of residence Geneva, Switzerland

Professional Development

Currently Chief Financial Officer, The Global Fund, Geneva, Switzerland
2011 – 2012 Senior Advisor at Roland Berger Strategy Consultants, Paris, France
2002 – 2011

Group Senior Executive Vice President, Group Chief Financial Officer, Head of International Activities and Strategy of EDF Group, France

1991 - 2002

Chief Financial Officer of Aventis Pharma AG, Frankfurt, Germany

Chief Financial Officer of Hoechst Marion Roussel AG, Frankfurt, Germany and Bridgewater (USA)

Chief Financial Officer of Roussel Uclaf SA, France

1976 - 1991 Business Development and Chief Financial Officer in affiliates of Hoechst AG Group in France, Canada and Germany

Education

1981 Economics Ph.D (Major in Finance), Paris Sorbonne University, France
1975 Major in Finance and Economics (Laureate), Institut d'Etudes Politiques de Paris, France
1974 Master in Economics, Nancy University, France

Membership in other Supervisory Boards and other current mandates

Cameco Corp.*, Canada Member of the Board of Directors
SGL Group SE, Germany Member of the Supervisory Board
Valéo SA*, France Member of the Board of Directors
Vivendi SA*, France Member of the Supervisory Board

Dr. Camus is a member of MorphoSys AG's Supervisory Board since 2002.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Dr. Marc Cluzel

Member

Biography and additional memberships

Dr. Marc Cluzel

Member

Year of birth 1955
Nationality French
Place of residence Montpellier, France

Professional Development

Since 2011 Founder and Consultant for C&F Consulting, Paris, France
Since 2011 Executive Vice President of Product Development at HÙYÀ Bioscience International, LLC
2009 - 2010 Executive Vice President of Research & Development of Sanofi, Paris France
2007 – 2009 Senior Vice President of Science and Medical Affairs of Sanofi, Paris, France
2002 – 2011 Chairman and Chief Executive Officer of Sanofi-Aventis R&D France, Paris, France
1996 – 2001 Head of Project Direction of Sanofi R&D
1993 – 1996 Project Director Sanofi R&D

Education

1983 - 1990 Ph.D. Biochemistry at University of Montpellier, France
1973 - 1985 Study of Medicine at University of Montpellier, France

Membership in other Supervisory Boards and other current mandates

Moleac Pte. Ltd.*, Singapore Member of the Board of Directors

Dr. Cluzel is a member of MorphoSys AG's Supervisory Board since 2012.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Karin Eastham

Member

Biography and additional memberships

Karin Eastham

Member

Year of birth 1949
Nationality American
Place of residence Rancho Santa Fe, CA, USA

Professional Development

Currently Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign Supervisory Boards of commercial enterprises, Rancho Santa Fe, CA, USA 
2004 – 2008 Executive Vice President and Chief Operating Officer of Burnham Institute for Medical Research, La Jolla, USA
1999 – 2004 Senior Vice President Finance, Chief Financial Officer and Secretary of Diversa Corporation, San Diego, USA
1988 – 1999 Similar financial leadership positions with CombiChem, Inc. and Cytel Corporation, USA
1976 – 1988 Several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, Indianapolis, USA

Education

1979 Master of Business Administration at the University of Indiana, USA
1973 Bachelor of Science at the University of Indiana, USA

Membership in other Supervisory Boards and other current mandates

AltheaDX*, USA Member of the Board of Directors
Geron Inc.*, USA Member of the Board of Directors
Illumina Inc.*, USA Member of the Board of Directors
Veracyte Inc.*, USA Member of the Board of Directors

Karin Eastham is a member of MorphoSys AG's Supervisory Board since 2012.

*) Membership in comparable domestic and foreign supervisory boards of commercial enterprises

Composition of the Supervisory Board

  Initial
Appointment
End of
Period 1
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Gerald Möller 1999 2015  
 
Dr. Geoffrey Vernon
1999 2015
   
Dr. Walter Blättler 2007 2015    
Dr. Daniel Camus
2002 2015
   
Dr. Marc Cluzel 2012 2015  
Karin Eastham
2012 2015
2
 

1 Period ends with termination of Annual General Meeting 2015 

Independent Financial Expert     Chairman     Member